Seres Therapeutics Inc (NASDAQ:MCRB)
| 3.64 Delayed Data As of Jul 01 |  +0.205 / +5.98%Today’s Change | 2.50 Today|||52-Week Range 23.89 | -56.36% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $450.1M |
Company Description
Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.
Contact Information
Seres Therapeutics, Inc. 200 Sidney Street Cambridge Massachusetts 02139 |
Employees
Shareholders
| Mutual fund holders | 39.68% |
| Other institutional | 25.96% |
| Individual stakeholders | 24.16% |
Top Executives
| Eric D. Shaff | President, Chief Executive Officer & Director |
| Marcus Chapman | Senior Vice President-Operations |
| David A. Arkowitz | EVP, Chief Financial & Accounting Officer |
| Matthew R. Henn | Chief Scientific Officer & Executive VP |
| Barbara McGovern | Vice President-Medical Affairs |
